RU2017126030A - Улучшенная вакцина против nd-ibd на основе вектора hvt - Google Patents
Улучшенная вакцина против nd-ibd на основе вектора hvt Download PDFInfo
- Publication number
- RU2017126030A RU2017126030A RU2017126030A RU2017126030A RU2017126030A RU 2017126030 A RU2017126030 A RU 2017126030A RU 2017126030 A RU2017126030 A RU 2017126030A RU 2017126030 A RU2017126030 A RU 2017126030A RU 2017126030 A RU2017126030 A RU 2017126030A
- Authority
- RU
- Russia
- Prior art keywords
- gene
- recombinant
- vaccine
- poultry
- ndv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16341—Use of virus, viral particle or viral elements as a vector
- C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (22)
1. Экспрессирующая кассета рекомбинантной ДНК, содержащая в направлении от 5' к 3' и в указанном порядке:
промотор предраннего гена 1 цитомегаловируса мыши (IE1 mCMV),
ген вирусного белка 2 (VP2) вируса инфекционного бурсита (IBDV),
терминатор транскрипции,
промотор предраннего гена 1 цитомегаловируса человека (IE1 hCMV),
ген белка слияния (F) вируса болезни Ньюкасла (NDV).
2. Экспрессирующая кассета рекомбинантной ДНК по п.1, где одно, или несколько, или все из используемых условий выбраны из группы, состоящей из следующего: промотор гена IE1 mCMV представляет собой полный промотор; ген VP2 IBDV кодирует белок VP2 IBDV классического типа; терминатор транскрипции содержит область терминатора и область поли-A; терминатор транскрипции получают из вируса обезьян 40 (SV40); промотор гена IE1 hCMV представляет собой основной промотор; ген F NDV получают из лентогенного штамма NDV; экспрессирующая кассета содержит дополнительный терминатор транскрипции, расположенный ниже гена F NDV; и дополнительный терминатор транскрипции получают из гена IE1 hCMV.
3. Молекула рекомбинантной ДНК, содержащая экспрессирующую кассету рекомбинантной ДНК по любому из пп. 1 или 2.
4. Рекомбинантный вирус герпеса индеек (HVT), содержащий экспрессирующую кассету рекомбинантной ДНК по любому из пп. 1 или 2, где экспрессирующая кассета вставлена в область US генома рекомбинантного HVT.
5. Клетка-хозяин, содержащая рекомбинантный HVT по п.4.
6. Способ конструирования рекомбинантного HVT по п.4, где указанный способ включает вставку экспрессирующей кассеты рекомбинантной ДНК по любому из пп. 1 или 2 в область US генома рекомбинантного HVT.
7. Вакцина для домашней птицы, содержащая рекомбинантный HVT по п.4 и/или клетку-хозяина по п.5 и фармацевтически приемлемый носитель.
8. Вакцина по п.7, содержащая по меньшей мере один дополнительный иммуноактивный компонент.
9. Способ получения вакцины по п.7, включающий стадии:
- инфицирования клеток-хозяев рекомбинантным HVT по п.4,
- сбора инфицированных клеток-хозяев и
- смешивания собранных инфицированных клеток-хозяев с фармацевтически приемлемым носителем.
10. Рекомбинантный HVT по п.4 для применения в вакцине для домашней птицы.
11. Применение экспрессирующей кассеты по любому из пп. 1 или 2, молекулы рекомбинантной ДНК по п.3, рекомбинантного HVT по п.4, клетки-хозяина по п.5 или любого их сочетания для получения вакцины для домашней птицы.
12. Применение вакцины по любому из пп. 7 или 8 для профилактики или снижения инфекции IBDV и/или NDV или ассоциированных симптомов заболевания.
13. Способ профилактики или снижения инфекции IBDV и/или NDV или ассоциированных симптомов заболевания, включающий введение домашней птице вакцины по любому из пп. 7 или 8.
14. Способ вакцинации домашней птицы, включающий стадию вакцинации указанной домашней птицы вакциной по любому из пп. 7 или 8.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14200340 | 2014-12-24 | ||
EP14200340.9 | 2014-12-24 | ||
PCT/EP2015/081121 WO2016102647A1 (en) | 2014-12-24 | 2015-12-23 | Improved hvt-vectored nd-ibd vaccine |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017126030A3 RU2017126030A3 (ru) | 2019-01-24 |
RU2017126030A true RU2017126030A (ru) | 2019-01-24 |
RU2692013C2 RU2692013C2 (ru) | 2019-06-19 |
Family
ID=52282550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017126030A RU2692013C2 (ru) | 2014-12-24 | 2015-12-23 | Улучшенная вакцина против nd-ibd на основе вектора hvt |
Country Status (12)
Country | Link |
---|---|
US (1) | US10308956B2 (ru) |
EP (1) | EP3185899B1 (ru) |
JP (1) | JP6246985B1 (ru) |
CN (1) | CN107002097B (ru) |
AR (1) | AR103245A1 (ru) |
BR (1) | BR112017013595A2 (ru) |
ES (1) | ES2648672T3 (ru) |
HU (1) | HUE035364T2 (ru) |
MX (1) | MX2017008504A (ru) |
PL (1) | PL3185899T3 (ru) |
RU (1) | RU2692013C2 (ru) |
WO (1) | WO2016102647A1 (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11596687B2 (en) | 2016-06-17 | 2023-03-07 | Intervet Inc. | Recombinant non-pathogenic Marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens |
KR102617503B1 (ko) * | 2016-12-14 | 2023-12-29 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 조류 병원체의 다중 항원을 발현하는 재조합 hvt 벡터 및 그를 포함하는 백신 |
CN107099513B (zh) * | 2017-06-22 | 2020-07-14 | 北京邦卓生物科技有限公司 | 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用 |
BR112020007213A2 (pt) | 2017-10-12 | 2020-10-13 | Intervet International B.V. | construtos de vírus da doença de marek não patogênico recombinante que codificam múltiplos antígenos heterólogos |
CN111542337A (zh) | 2017-12-20 | 2020-08-14 | 英特维特国际股份有限公司 | 用于细胞相关联的α疱疹病毒疫苗的改良稀释剂 |
CN109320594B (zh) * | 2018-11-13 | 2021-09-28 | 四川大学 | 一种禽传染性支气管炎和新城疫的病毒样颗粒、制备方法及应用 |
CN110331135A (zh) * | 2019-07-18 | 2019-10-15 | 扬州大学 | 表达基因vii型新城疫病毒融合蛋白的重组火鸡疱疹病毒候选疫苗株及制备方法 |
CA3153379A1 (en) | 2019-09-11 | 2021-03-18 | Zoetis Services Llc | Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof |
US20230031097A1 (en) | 2019-12-20 | 2023-02-02 | Intervet Inc. | Multivalent hvt vector vaccine |
IL299033A (en) | 2020-06-17 | 2023-02-01 | Boehringer Ingelheim Vetmedica Gmbh | Recombinant HVT vectors expressing influenza hemagglutinin and immunogenic compounds, production and uses thereof |
BR112023004123A2 (pt) | 2020-09-07 | 2023-04-04 | Intervet Int Bv | Vacina de haste da ha para alvos positivos de anticorpos de ha |
CN112501139B (zh) * | 2020-12-11 | 2023-03-21 | 新乡学院 | 一株重组新城疫病毒毒株及其制备方法和应用 |
EP4267179A1 (en) | 2020-12-24 | 2023-11-01 | Intervet International B.V. | Multivalent hvt vector vaccine |
WO2023213946A1 (en) | 2022-05-05 | 2023-11-09 | Intervet International B.V. | New multivalent hvt vector vaccine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5928648A (en) | 1985-09-06 | 1999-07-27 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
US5965138A (en) | 1985-09-06 | 1999-10-12 | Syntro Corporation | Recombinant chimeric virus and uses thereof |
US5961982A (en) | 1985-09-06 | 1999-10-05 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
WO1987004463A1 (en) * | 1986-01-27 | 1987-07-30 | Syntro Corporation | Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same |
GB8603341D0 (en) | 1986-02-11 | 1986-03-19 | Portapax Ltd | Foam sheet |
ES2070997T3 (es) | 1989-12-04 | 1995-06-16 | Akzo Nobel Nv | Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos. |
FR2728795B1 (fr) | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
US6632664B1 (en) | 1997-10-03 | 2003-10-14 | Nippon Zeon Co., Ltd. | Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same |
US6764684B2 (en) | 2001-09-28 | 2004-07-20 | Zeon Corporation | Avian herpesvirus-based recombinant infectious bursal disease vaccine |
JP2011525519A (ja) | 2008-06-23 | 2011-09-22 | インターベツト・インターナシヨナル・ベー・ベー | インターロイキン12をコードするシチメンチョウの組換えヘルペスウイルス |
EP2768529A1 (en) * | 2011-10-21 | 2014-08-27 | Intervet International B.V. | Recombinant nonpathogenic mdv vector providing multivalent immunity |
BR112014009565A2 (pt) * | 2011-10-21 | 2017-04-18 | Intervet Int Bv | vírus da doença de marek não patogênico recombinante, ácido nucleico recombinante, vacina, e, método para ajudar na proteção de um frango contra vírus |
US9114108B2 (en) | 2011-11-30 | 2015-08-25 | Merial, Inc. | Recombinant HVT vectors expressing antigens of avian pathogens and uses thereof |
SI2785373T1 (sl) * | 2011-11-30 | 2020-02-28 | Boehringer Ingelheim Animal Health USA Inc. | Rekombinantni vektorji HVT, ki izražajo antigene aviarnih patogenov in uporabe le-teh |
EP2644702A1 (en) | 2012-03-30 | 2013-10-02 | Ceva Sante Animale | Multivalent recombinant avian herpes virus and vaccine for immunizing avian species |
BR112017011582A2 (pt) | 2014-12-04 | 2018-02-27 | Intervet Int Bv | fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina. |
-
2015
- 2015-12-22 AR ARP150104255A patent/AR103245A1/es unknown
- 2015-12-23 CN CN201580070228.0A patent/CN107002097B/zh active Active
- 2015-12-23 BR BR112017013595A patent/BR112017013595A2/pt unknown
- 2015-12-23 HU HUE15817860A patent/HUE035364T2/en unknown
- 2015-12-23 PL PL15817860T patent/PL3185899T3/pl unknown
- 2015-12-23 JP JP2017533847A patent/JP6246985B1/ja active Active
- 2015-12-23 ES ES15817860.8T patent/ES2648672T3/es active Active
- 2015-12-23 RU RU2017126030A patent/RU2692013C2/ru active
- 2015-12-23 EP EP15817860.8A patent/EP3185899B1/en active Active
- 2015-12-23 US US15/110,628 patent/US10308956B2/en active Active
- 2015-12-23 WO PCT/EP2015/081121 patent/WO2016102647A1/en active Application Filing
- 2015-12-23 MX MX2017008504A patent/MX2017008504A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MX2017008504A (es) | 2017-10-11 |
RU2017126030A3 (ru) | 2019-01-24 |
PL3185899T3 (pl) | 2018-01-31 |
EP3185899A1 (en) | 2017-07-05 |
BR112017013595A2 (pt) | 2018-03-06 |
US10308956B2 (en) | 2019-06-04 |
JP2018501792A (ja) | 2018-01-25 |
WO2016102647A1 (en) | 2016-06-30 |
ES2648672T3 (es) | 2018-01-05 |
CN107002097A (zh) | 2017-08-01 |
EP3185899B1 (en) | 2017-10-18 |
JP6246985B1 (ja) | 2017-12-13 |
HUE035364T2 (en) | 2018-05-02 |
US20170306353A1 (en) | 2017-10-26 |
CN107002097B (zh) | 2021-06-15 |
AR103245A1 (es) | 2017-04-26 |
RU2692013C2 (ru) | 2019-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017126030A (ru) | Улучшенная вакцина против nd-ibd на основе вектора hvt | |
RU2014120408A (ru) | Рекомбинантный непатогенный mdv-вектор, обеспечивающий полиспецифический иммунитет | |
Liu et al. | A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks | |
Hein et al. | Review of poultry recombinant vector vaccines | |
RU2018116857A (ru) | Мультивалентные рекомбинантные вирусы птичьего герпеса и вакцины для иммунизации птиц | |
RU2014120471A (ru) | Конструкции рекомбинантного непатогенного вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса болезни ньюкасла | |
García et al. | Commercial vaccines and vaccination strategies against infectious laryngotracheitis: what we have learned and knowledge gaps that remain | |
JP2017522907A5 (ru) | ||
JP2015500806A5 (ru) | ||
RU2016112951A (ru) | Рекомбинанатные вирусы болезни марека и их применение | |
Ravikumar et al. | Vaccines against major poultry viral diseases: strategies to improve the breadth and protective efficacy | |
Yang et al. | Recombinant infectious bronchitis virus (IBV) H120 vaccine strain expressing the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) protects chickens against IBV and NDV challenge | |
Lee et al. | Growth kinetics and transmission potential of existing and emerging field strains of infectious laryngotracheitis virus | |
Zhang et al. | Protection conferred by a recombinant Marek’s disease virus that expresses the spike protein from infectious bronchitis virus in specific pathogen-free chicken | |
Gimeno et al. | Evaluation of the protection efficacy of a serotype 1 Marek's disease virus-vectored bivalent vaccine against infectious laryngotracheitis and Marek's disease | |
RU2019102170A (ru) | Вирус утиного энтерита и его применение | |
CN103173455B (zh) | 一种具有抗新城疫病毒活性的鹅源基因rig-i及其应用 | |
CN103740759A (zh) | 表达h5n1亚型禽流感病毒ha基因的重组火鸡疱疹病毒 | |
CN103627718A (zh) | 表达ibv s1和n双抗原蛋白重组质粒及其构建方法和应用 | |
Guo et al. | Recombinant infectious hematopoietic necrosis virus expressing infectious pancreatic necrosis virus VP2 protein induces immunity against both pathogens | |
Kim et al. | Vaccinal efficacy of molecularly cloned Gallid alphaherpesvirus 3 strain 301B/1 against very virulent Marek’s disease virus challenge | |
CN101066448A (zh) | 重组鸡痘病毒疫苗rFPV-1218AIH5/H9及其构建方法、用途 | |
CN104164410A (zh) | 一种鸡新城疫病毒毒株及其在制备鸡新城疫病疫苗中的应用 | |
CN1718242A (zh) | 狂犬病病毒糖/核等结构蛋白的犬2型腺病毒重组疫苗 | |
Goudarzi et al. | Characterization and full genome sequencing of a velogenic Newcastle disease virus (NDV) strain Ck/IR/Beh/2011 belonging to subgenotype VII (L). |